Prior authorization for selected procedure codes

Certain procedure codes (for example, intralesional injections [11900/11901], PUVA photochemotherapy [96912], platelet-rich plasma injections [0232T], extracorporeal photopheresis [36522], hematopoietic progenitor cell harvesting [38205/38206], and HLA Class II typing [81382]) are listed in the policy and may require prior authorization or meeting selection criteria for coverage.

• Prior authorization may be required when selection criteria apply for the listed CPT/HCPCS codes.
• Providers should verify plan-specific PA requirements before billing these procedure codes for alopecia areata.

PA recommended for novel/off‑label treatments (e.g., brevilin A, carboxytherapy)

Off‑label or novel therapies that are reported only in small case series or preliminary trials (for example, brevilin A or carboxytherapy) generally require prior authorization with submission of supporting evidence such as baseline and follow‑up SALT scores and safety monitoring.

• Brevilin A: small case‑series (n=13) showed no statistically significant improvement; further studies needed.
• Carboxytherapy: a 3‑month study (AA and AGA) reported improvement but recommended more sessions and maintenance; prior authorization and documentation of rationale are advised.

PA may be required for device‑based treatments (excimer, fractional CO2, etc.)

Prior authorization may be appropriate for device‑based or procedural therapies (such as excimer laser, fractional CO2 laser, or other laser/light modalities) because evidence is limited and documentation of prior standard therapies and objective baseline severity is expected.

• Excimer laser: meta‑analysis of small studies reported cosmetically acceptable regrowth in ~50% but larger trials are limited.
• Fractional CO2: small case series and comparative studies report promising results; document prior treatment failure and baseline measures.

PA for investigational biologic/regenerative therapies (MSCs, advanced PRF)

Investigational therapies with very limited or preliminary evidence (for example, mesenchymal stem cell injections, advanced platelet‑rich fibrin/protocols) may require prior authorization because available data are small, heterogeneous, and insufficient to support routine coverage.

• WJ‑MSC intradermal injection: uncontrolled pilot (n=4) reported hair regrowth but sample size was very small.
• PRP/aPRF: systematic reviews note low‑quality, heterogeneous evidence; PA may be required with justification.

PA recommended for experimental/off‑label systemic or device therapies

Prior authorization is recommended for experimental or off‑label systemic combinations and device/procedure‑based treatments (for example, simvastatin/ezetimibe combinations or laser/light therapies) because evidence is limited and variable; include prior treatment history and clinical rationale.

• Simvastatin/ezetimibe: small prospective studies reported inconsistent/unsatisfactory remission rates and recommend randomized trials.
• Laser/light + minoxidil: meta‑analyses show variable, low‑to‑moderate quality evidence; PA should include prior therapies tried.

Follow payer prior authorization processes

Providers must follow the payer's prior authorization processes: the Clinical Policy Bulletin informs coverage decisions, but plan‑specific PA requirements and procedures must be used when applicable.

• Submit documentation consistent with plan PA forms and timelines.
• Meeting CPB selection criteria does not replace any required PA submission under member benefits.

Sequence therapy by severity (topicals/intralesional first for mild; systemic/PUVA for extensive)

Therapy choices should be sequenced by disease severity: mild alopecia areata (<50% scalp hair loss) is commonly managed with topical anthralin and topical or intralesional corticosteroids, while extensive disease (>50%) may require systemic glucocorticoids, PUVA, or topical immunotherapy after conventional therapies fail.

• Mild: topical anthralin; topical/intralesional glucocorticoids (average 4–6 monthly intralesional injections).
• Extensive: anthralin, oral/topical/intralesional glucocorticoids, PUVA, and topical immunotherapy (DPCP/SADBE) when conventional therapies have failed.

Require standard therapies before newer agents (step therapy principle)

Established, guideline‑supported therapies (for example, topical and intralesional corticosteroids, sensitizing agents) should generally be tried before newer or unconventional agents; consider step therapy that requires trials of standard treatments prior to approval of novel agents.

• Many RCTs and reviews identify topical/systemic corticosteroids and sensitizers as among treatments with demonstrated benefit.
• Newer agents should be considered after inadequate response or contraindication to standard therapies.

Consider topical/intralesional steroids or contact immunotherapy as prior therapies

Consider evidence‑based prior therapies such as topical high‑potency steroids, intralesional corticosteroids, or contact immunotherapies (e.g., diphencyprone, Candida antigen) as documented prior therapy steps before approving adjunctive or investigational treatments.

• Intralesional corticosteroids are the most common treatment for mild patchy AA (4–6 monthly injections).
• Contact immunotherapy (DCP, Candida antigen) has shown variable benefit in multiple studies and may be a reasonable prior step.

Prefer guideline‑supported first‑line therapies before adjunctive options

Preference should be given to established first‑line therapies (such as topical high‑potency steroids and intralesional corticosteroids) and documented trials of these should be required before considering adjunctive or investigational options like PRP or LLLT.

• Minoxidil (5%) has moderate‑quality evidence for patchy AA and may be used as a standard therapy.
• PRP evidence is limited/low quality; consider it only after standard therapies have been tried and documented.

Require trials of standard therapies before experimental/adjunctive options

Require documented trials of standard, evidence‑supported topical or intralesional therapies before approving unconventional, experimental, or adjunctive modalities (for example topical calcipotriol monotherapy or laser/light combined with minoxidil).

• Topical calcipotriol: retrospective data suggest possible benefit but larger controlled trials are needed.
• Laser/light + minoxidil: meta‑analysis shows potential benefit but evidence quality is very low to moderate—document prior standard therapy trials.

Document clinical diagnosis and extent (exclamation‑mark hairs, patch size, percent scalp involvement)

Diagnosis of alopecia areata is clinical and documentation should include typical findings (for example, exclamation‑mark hairs, patch size, rapid onset) and the extent of scalp involvement to support classification as mild versus extensive.

• Record presence of exclamation‑mark hairs, patch dimensions, onset timing, and any nail pitting.
• Document percent scalp involvement to determine mild (<50%) versus extensive (>50%) disease.

Document indication, prior therapies, and objective severity (SALT) for investigational/off‑label requests

When requesting coverage for investigational or off‑label therapies, include documentation of the indication, prior therapies tried and responses, objective severity measurement (e.g., SALT score), proposed regimen and duration, and safety monitoring to support medical necessity.

• Provide baseline and follow‑up SALT scores where available.
• List prior systemic/topical/ procedural therapies, dates, doses, and documented responses or failures.

Document prior treatments, indication, baseline severity, and informed consent for device/procedural therapies

For device‑ or procedure‑based treatments (for example, fractional CO2 laser, excimer laser), document prior treatment history, the specific indication (resistant or recalcitrant AA), baseline severity (e.g., SALT score or photographic documentation), and informed consent acknowledging limited/preliminary evidence.

• Include prior modalities tried and dates (topical, intralesional, systemic, PUVA, immunotherapy).
• Attach baseline photos and objective measures to support necessity for device therapy.

Suggested documentation: indication, prior treatments/responses, regimen and duration

Suggested documentation elements to support medical necessity include the indication (AA subtype and severity, e.g., SALT score), prior treatments and responses, proposed regimen and duration, and informed consent noting investigational or limited evidence status for the requested therapy.

• Baseline disease severity (SALT or percent bald surface) and photographic documentation.
• Specific proposed treatment plan with frequency, duration, and monitoring parameters.

Document baseline severity, prior treatments, and specific regimen/duration to justify medical necessity

To support medical necessity requests, document baseline severity (e.g., SALT score or percent bald surface), prior therapies tried and their documented responses, and the specific regimen and duration planned for the requested treatment.

• When using unconventional/off‑label therapies (e.g., bimatoprost, simvastatin/ezetimibe, calcipotriol, laser + minoxidil), include peer‑reviewed justification and prior failed treatments.
• Report objective follow‑up measures to demonstrate response.

Provider responsibility for clinical care; CPB aids benefit administration

Treating providers are responsible for clinical assessment and treatment decisions; the Clinical Policy Bulletin is intended to aid benefit administration but does not replace professional medical judgment.

• Providers must supply necessary clinical documentation to support coverage determinations.
• CPBs provide plan administration guidance and are not the sole determinant of individual patient care.

Not‑covered services listed may be denied

Services and tests explicitly listed as not covered in the policy (for example, certain gene polymorphism testing, carboxytherapy, cryotherapy, fractional CO2 laser when listed as not covered, and platelet‑rich fibrin/PRP when indicated as not covered) may be denied if billed for alopecia areata indications.

• Verify whether a given procedure code is designated as not covered for the specific indication before billing.
• Denial is possible when services are billed for AA but are listed as not covered in the CPB.

Limited RCT evidence can trigger denial

Treatments supported only by low‑quality or limited randomized controlled trial evidence may be considered investigational or not medically necessary and could trigger coverage denial.

• The policy notes many RCTs are moderate quality and several therapies need larger, rigorous trials before routine use.
• Providers should expect possible denial for therapies lacking convincing RCT support.

Routine trace element or iron testing not routinely recommended

Routine laboratory testing of iron status or trace elements (for example, serum iron, ferritin, zinc, selenium) is not routinely recommended as a diagnostic tool for alopecia areata and may not be supported for coverage absent specific clinical indications.

• Guidelines state investigations are unnecessary in most cases and routine iron testing is not recommended.
• Meta‑analyses show inconsistent findings; routine testing without clinical suspicion is not supported.

Evidence‑limited therapies (PRP, aPRF, MSCs, LLLT, intralesional methotrexate) are at higher denial risk

Interventions with limited, inconsistent, or low‑quality evidence (such as PRP, autologous platelet‑rich fibrin, mesenchymal stem cells, low‑level laser therapy, intralesional Candida antigen, or intralesional methotrexate for localized AA) may be at risk for coverage denial or require prior authorization because high‑quality supporting evidence is lacking.

• PRP: systematic reviews/meta‑analyses rate evidence as low quality and heterogeneous.
• WJ‑MSC pilot studies are very small (n=4) and considered investigational.

Evidence‑limited therapies may require extra justification or trial documentation

Therapies supported only by preliminary, low‑quality, or single‑center data (for example, topical calcipotriol, simvastatin/ezetimibe, laser/light combinations) may require additional clinical justification, documentation of prior standard therapies, or enrollment in clinical trials to be considered for coverage.

• Simvastatin/ezetimibe studies are small and inconsistent; authors recommend randomized trials.
• Topical calcipotriol has only retrospective data; laser/light evidence is variable—provide extra justification when requesting coverage.

Denials triggered by missing documentation or unmet policy criteria

Coverage and medical necessity determinations are governed by the Clinical Policy Bulletin; lack of required documentation or failure to meet the policy’s selection criteria can result in denial of coverage.

• Ensure submitted records meet the CPB criteria and include requested objective measures and prior treatment history.
• Incomplete documentation or absence of required prior therapy trials may lead to claim denial.